Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study

scientific article published on 8 March 2004

Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/01.CIR.0000121736.16643.11
P698PubMed publication ID15007003
P5875ResearchGate publication ID7780240

P50authorEleanor B SchronQ117272038
P2093author name stringAlbert L Waldo
H Leon Greene
John P DiMarco
Scott D Corley
Yves Rosenberg
Andrew E Epstein
D George Wyse
L Brent Mitchell
Andrew D Krahn
Nancy Geller
Richard A Josephson
Lynn Shemanski
Michael J Domanski
Richard C Klein
AFFIRM Investigators
Mary Mickel
Joyce C Kellen
Joy Dalquist Nelson
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectatrial fibrillationQ815819
P304page(s)1509-1513
P577publication date2004-03-08
P1433published inCirculationQ578091
P1476titleRelationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
P478volume109

Reverse relations

cites work (P2860)
Q379898372012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design
Q306530452014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures
Q273418732014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society
Q36446641A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record
Q53383705A pilot study to assess benefit of atrial rhythm control after cardiac resynchronization therapy and atrioventricular node ablation.
Q38654100A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial
Q22306351ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
Q46734928AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat.
Q37495744Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends
Q81806274Ablation of atrial fibrillation: patient selection, technique, and outcome
Q36867280Ablation should not be first-line therapy for the treatment of atrial fibrillation
Q51062071Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.
Q38151445Addressing the controversy of rate-versus-rhythm control in atrial fibrillation
Q42777572Advances in the Pharmacologic Management of Atrial Fibrillation
Q34383573Advances in the Pharmacological Treatment of Atrial Fibrillation
Q38076142Advances in the management of atrial fibrillation.
Q38822819Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.
Q58743469Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging
Q37472036Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone
Q39564664Antiarrhythmic properties of ranolazine--from bench to bedside
Q38124871Antiarrhythmic therapy following ablation of atrial fibrillation
Q97424445Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation
Q28268244Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management
Q87919168Arrhythmias: Atrial fibrillation in heart failure - time to revise the guidelines?
Q36114623Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study
Q41988070Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter
Q48525838Atrial Fibrillation Ablation and its Impact on Stroke.
Q39300446Atrial Fibrillation Ablation: First-Line Therapy?
Q33574018Atrial Fibrillation And Coronary Heart Disease:Fatal Attraction
Q35901629Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey
Q37114460Atrial Fibrillation and Heart Failure
Q38597936Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An National Cardiovascular Data Registry (NCDR®) Research to Practice (R2P) Project
Q41686261Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times.
Q37495914Atrial Fibrillation in Patients with Ischemic and Non-Ischemic Left Ventricular Dysfunction
Q34175991Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial
Q35292524Atrial fibrillation ablation in systolic dysfunction: clinical and echocardiographic outcomes
Q43012181Atrial fibrillation ablation in the real world
Q37155980Atrial fibrillation and congestive heart failure
Q36836836Atrial fibrillation and stroke: the evolving role of rhythm control
Q33954432Atrial fibrillation in congestive heart failure
Q38032181Atrial fibrillation in heart failure
Q50099027Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken and the egg.
Q38153249Atrial fibrillation in heart failure: catheter and surgical interventional therapies
Q26784426Atrial fibrillation in heart failure: what should we do?
Q37882717Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly
Q84856755Atrial fibrillation in the elderly
Q58555771Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study
Q39957513Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors
Q38006746Atrial fibrillation, stroke, and quality of life
Q37923979Atrial fibrillation: an epidemic in the elderly
Q37476763Atrial fibrillation: challenges and opportunities
Q37483061Atrial fibrillation: cure or treat?
Q34747164Atrial fibrillation: current concepts
Q34986419Atrial fibrillation: current perspective
Q26864877Atrial fibrillation: effects beyond the atrium?
Q37848443Atrial fibrillation: pathophysiology and current therapy
Q37811048Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?
Q37494653Atrial-selective sodium channel block for the treatment of atrial fibrillation.
Q39109570Biatrial ablation vs. left atrial concomitant surgical ablation for treatment of atrial fibrillation: a meta-analysis.
Q41332447Blood Pressure and Atrial Fibrillation: A Combined AF-CHF and AFFIRM Analysis.
Q38469887Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure
Q92840714Budget Impact of Cryoablation Versus Radiofrequency Ablation of Atrial Fibrillation in the Brazilian Public Healthcare System
Q45122374CARTO-guided vs. NavX-guided pulmonary vein antrum isolation and pulmonary vein antrum isolation performed without 3-D mapping: effect of the 3-D mapping system on procedure duration and fluoroscopy time
Q38973172CHA2DS2-VASc risk factors as predictors of stroke after acute coronary syndrome: A systematic review and meta-analysis
Q37761072Can ablation prevent the excess mortality of atrial fibrillation?
Q35954783Can atrial fibrillation with a coarse electrocardiographic appearance be treated with catheter ablation of the tricuspid valve-inferior vena cava isthmus? Results of a multicentre randomised controlled trial.
Q46787245Can recent-onset atrial fibrillation be safely and successfully treated with self-administered antiarrhythmic drugs?
Q33516708Can we improve outcomes in AF patients by early therapy?
Q39300661Cardiac Resynchronization Therapy and Atrial Fibrillation
Q81431685Cardiac dimensions and function in atrial fibrillation: how do rate and rhythm control compare?
Q38201409Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia
Q81388943Cardiomyopathy induced by pulmonary vein tachycardia cured by catheter ablation
Q36584176Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study
Q35790082Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
Q37573899Cardioversion for atrial fibrillation: treatment options and advances
Q35918565Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials
Q60922066Catheter Ablation for Atrial Fibrillation in Systolic Heart Failure Patients: Stone by Stone, a CASTLE
Q42134338Catheter Ablation of Atrial Fibrillation - Techniques and Technology
Q36141391Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Q53276291Catheter ablation as first-line in atrial fibrillation: is rhythm control finally better than rate control?
Q36867275Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation
Q47119395Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis
Q56986662Catheter ablation for atrial fibrillation
Q31059405Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.
Q37546138Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure
Q38726564Catheter ablation of atrial fibrillation in chronic heart failure: state-of-the-art and future perspectives
Q86575757Catheter ablation of atrial fibrillation in patients with heart failure: can we break the vicious circle?
Q53028592Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function.
Q38087518Catheter ablation of atrial fibrillation to reduce stroke risk
Q91084221Catheter ablation of atrial fibrillation-A key role in heart failure therapy?
Q80113135Catheter ablation of atrial fibrillation: a treatment frontier
Q35771196Catheter ablation of permanent atrial fibrillation: medium term results
Q27002352Catheter ablation versus rate control for atrial fibrillation: what have we learnt from the ARC-HF trial?
Q42673198Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
Q43109711Chronotropic Incompetence and Risk of Atrial Fibrillation: The Henry Ford ExercIse Testing (FIT) Project.
Q57627137Clinical Trials on Atrial Fibrillation/Future Perspectives
Q64069343Clinical and Echocardiographic Risk Factors Predict Late Recurrence after Radiofrequency Catheter Ablation of Atrial Fibrillation
Q64996273Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry.
Q37538004Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.
Q45267016Clinical experience with routine use of a single combined mapping and ablation catheter for isolation of pulmonary veins in patients with paroxysmal atrial fibrillation
Q45249251Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift
Q38095871Clinical update on the management of atrial fibrillation.
Q38666884Comorbidity of atrial fibrillation and heart failure
Q37495724Comparing Safety and Efficacy of Irrigated Radiofrequency Catheter Ablation Versus Combined Cryoballoon and Catheter Ablation for Persistent Atrial Fibrillation
Q84471438Comparing ablation and antiarrhythmic drug therapy for atrial fibrillation
Q36587229Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review
Q35772224Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.
Q38790389Connexin Remodeling Contributes to Atrial Fibrillation
Q38435600Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation.
Q36590816Contact forces during hybrid atrial fibrillation ablation: an in vitro evaluation
Q38970521Contemporary Controversies in Digoxin Use in Systolic Heart Failure
Q39037010Control Of Hypertension Improves The Outcome Of Therapies For Paroxysmal And Persistent Atrial Fibrillation
Q36374193Controversies in atrial fibrillation
Q43050046Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Q51104318Cost comparison of catheter ablation and medical therapy in atrial fibrillation.
Q35832134Cost considerations in the management of atrial fibrillation - impact of dronedarone
Q36382393Cost of atrial fibrillation: invasive vs non-invasive management in 2012
Q35885128Costs and clinical consequences of suboptimal atrial fibrillation management
Q37914056Cryoablation of atrial fibrillation
Q81154624Curative catheter ablation for atrial fibrillation
Q36458858Current Evidence and Recommendations for Rate Control in Atrial Fibrillation
Q39300519Current Perspectives: Rheumatic Atrial Fibrillation
Q41835646Current ablation strategies for persistent and long-standing persistent atrial fibrillation
Q46271907Current atrial fibrillation guidelines and therapy algorithms: are they adequate?
Q36072140Current issues in atrial fibrillation
Q42760734Current management of atrial fibrillation: rhythm or rate control and thoughts about a new treatment paradigm
Q46150475Current strategies in the treatment of atrial fibrillation
Q39036995Destruction Of Medium Already Afected By Destructive Disorder: Fibrillating Atria Conceptually Need Therapeutic Help Rather Than Surgical Or Ablative Destruction
Q34660772Digoxin and mortality in atrial fibrillation: a prospective cohort study
Q35102218Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study
Q36321059Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction
Q31156918Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data
Q57809106Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation
Q31061099Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies
Q34068742Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy
Q42952490Dronedarone: NICE enough?
Q47573550Dronedarone: a new hope for stroke prevention in atrial fibrillation?
Q37736953Dronedarone: an emerging therapy for atrial fibrillation
Q37899900Dronedarone: an overview
Q34239793Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation
Q37767425Drug-induced QT-interval prolongation: considerations for clinicians
Q37717862Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation
Q51120485Dual-chamber pacemakers as long-term telemetry devices: ready for prime-time in diagnosing unsuspected atrial fibrillation?
Q39097180Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately
Q37521378Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'.
Q35648223Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation
Q45960286Early increase of NOX2-derived oxidative stress in children: relationship with age.
Q37737560Early management of atrial fibrillation: from imaging to drugs to ablation
Q37495815Effect of Age on Outcomes of Catheter Ablation of Atrial Fibrillation
Q47106384Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation
Q36077080Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation
Q47134346Effectiveness of catheter ablation of atrial fibrillation: are we at the dawn of a new era?
Q36325590Efficacy and effects on cardiac function of radiofrequency catheter ablation vs. direct current cardioversion of persistent atrial fibrillation with left ventricular systolic dysfunction
Q37650575Efficacy and safety of dronedarone: a review of randomized trials
Q38386998Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
Q51116249Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials.
Q59200971Eicosapentaenoic Acid for the Prevention of Recurrent Atrial Fibrillation
Q36793204Electrical cardioversion for AF-the state of the art.
Q24246610Electrical cardioversion for atrial fibrillation and flutter
Q26796261European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society
Q38571627European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.
Q82079500Exercise heart rate acceleration patterns during atrial fibrillation and sinus rhythm
Q37495738Exploring the Potential Role of Catheter Ablation in Patients with Asymptomatic Atrial Fibrillation: Should We Move away from Symptom Relief?
Q94263931External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta‐analysis
Q47663774Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation.
Q38897899Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism
Q89320643Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults
Q50941064From left bundle branch block to Icelandic whales: the multiple perils of atrial fibrillation management in the elderly.
Q36876093Genetic mechanisms of atrial fibrillation: impact on response to treatment
Q38894994Genotype influence in responses to therapy for atrial fibrillation
Q93160912Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation
Q35138993Heart failure and atrial fibrillation: from basic science to clinical practice
Q43918168Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey
Q30881762Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort.
Q35677371Heart rate is associated with progression of atrial fibrillation, independent of rhythm
Q35036404Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial
Q36021753How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Q44054562How much atrial fibrillation causes symptoms of heart failure?
Q55295121How to manage various arrhythmias and sudden cardiac death in the cardiovascular intensive care.
Q36624404Impact of Awareness and Patterns of Nonhospitalized Atrial Fibrillation on the Risk of Mortality: The Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study
Q34146486Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy
Q36569905Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone
Q89878618Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry
Q36456002Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.
Q35059670Improving ablation strategies for the treatment of atrial fibrillation
Q53602857Inadvertent toxic drug reaction in the management of atrial fibrillation.
Q37862925Incidental atrial fibrillation and its management
Q35511302Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study
Q37770108Interventional management of atrial fibrillation
Q43858415Is appropriate management of atrial fibrillation in primary care a utopia?
Q57214621Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea
Q57249882La fibrillation atriale est-elle un marqueur indépendant de risque cardio-vasculaire ?
Q36860117Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial
Q45034511Late thromboembolic events after circumferential pulmonary vein ablation of atrial fibrillation
Q47263839Left Atrial Size and Left Ventricular End-Systolic Dimension Predict the Progression of Paroxysmal Atrial Fibrillation After Catheter Ablation.
Q48184324Left atrial concomitant surgical ablation for treatment of atrial fibrillation in cardiac surgery: A meta-analysis of randomized controlled trials.
Q126659203Lenient versus Strict Rate Control in Atrial Fibrillation
Q39300535Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy
Q94595345Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure
Q44427484Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation
Q81446072Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised
Q39064825MEDEX South Carolina: a progress report
Q39026788Management of Atrial Fibrillation in Elderly Adults
Q51735257Management of Atrial Fibrillation.
Q28217428Management of atrial fibrillation
Q79917090Management of atrial fibrillation
Q80815086Management of atrial fibrillation
Q87752222Management of atrial fibrillation
Q37417705Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation.
Q36441982Management of atrial fibrillation--what are the possibilities of early detection with home monitoring?
Q35167436Management of patients with atrial fibrillation: specific considerations for the old age.
Q38534063Management of tachycardia
Q37115340Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation
Q38056113Management of ventricular and atrial arrhythmias in humans: towards a patient-specific approach
Q52811915Management strategies for atrial fibrillation.
Q35702394Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
Q37659215Managing atrial fibrillation in the global community: The European perspective
Q36580667Medical management of atrial fibrillation: state of the art.
Q91279118Meta-analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction
Q39036947Monitoring Atrial Fibrillation After Catheter Ablation.
Q33768807Mortality, stroke, and heart failure in atrial fibrillation cohorts after ablation versus propensity-matched cohorts
Q53318291Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation.
Q37697498New developments in atrial antiarrhythmic drug therapy
Q37770107New-onset atrial fibrillation and acute coronary syndrome
Q44846398New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey
Q36370426Non-pharmacological treatment of arrhythmias
Q37551914Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil
Q37946861Novel anticoagulants for atrial fibrillation: a critical appraisal
Q37481193Novel approaches for pharmacological management of atrial fibrillation.
Q35489060Novel pharmacological targets for the rhythm control management of atrial fibrillation.
Q42748645Opposing conclusions from post hoc analyses of the AFFIRM trial: was propensity score analysis to blame or just an innocent victim?
Q37468892Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?
Q36802853Optimization of Stroke Prophylaxis Strategies in Nonvalvular AF - Drugs, Devices or Both?
Q37766393Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations
Q36720925Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation
Q46538287PAFAC Study. Secondary prevention of atrial fibrillation after cardioversion
Q37338932Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management
Q37134738Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study
Q56864031Pharmacological therapy for atrial fibrillation: current options and new agents
Q83866919Pharmacotherapy for atrial fibrillation: is rhythm control achievable?
Q37123391Pharmacotherapy of atrial fibrillation: an old option with new possibilities
Q60138050Point-by-point pulmonary vein antrum isolation guided by intracardiac echocardiography and 3D mapping and duty-cycled multipolar AF ablation: effect of multipolar ablation on procedure duration and fluoroscopy time
Q38253047Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals
Q44754230Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation.
Q35151045Predictors and risk of pacemaker implantation after the Cox-maze IV procedure
Q37252892Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibrillation
Q89092899Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk
Q34389483Present concepts in management of atrial fibrillation: From drug therapy to ablation
Q84596232Pulmonary vein antrum isolation, atrioventricular junction ablation, and antiarrhythmic drugs combined with direct current cardioversion: survival rates at 7 years follow-up
Q37656335Pulmonary vein isolation for the treatment of atrial fibrillation: past, present and future
Q90467854Pulmonary vein volume predicts the outcome of radiofrequency catheter ablation of paroxysmal atrial fibrillation
Q42359516Putative Role of Right Atrial Ablation in Atrial Fibrillation
Q36147009Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
Q37496104Rate Control in Atrial Fibrillation: Avoiding Morbidity
Q33585592Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?
Q38936964Rate control in atrial fibrillation
Q35773042Rate control in the medical management of atrial fibrillation
Q36077780Rate control vs. rhythm control in the management of atrial fibrillation in elderly persons
Q36214675Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
Q36269171Rate versus rhythm control in the management of patients with atrial fibrillation
Q51361316Rate versus rhythm control strategies for AF.
Q46167374Rate versus rhythm control with and without heart failure
Q28200383Rate-control or rhythm-control: where do we stand?
Q37283337Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation
Q27692632Rationale and current perspective for early rhythm control therapy in atrial fibrillation.
Q38881287Reframing the association and significance of co-morbidities in heart failure
Q34161171Responsiveness of AF6, a new, short, validated, atrial fibrillation-specific questionnaire--symptomatic benefit of direct current cardioversion
Q79414555Restoring normal sinus rhythm in atrial fibrillation : evidence from pharmacologic therapy and catheter ablation trials
Q37845022Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation
Q38199620Revisiting heart activation-conduction physiology, part I: atria.
Q92277166Rhythm Control in AF: Have We Reached the Last Frontier?
Q92219072Rhythm Management of the Atrial Fibrillation Patient: Practical Implementation of the 2012 ESC Guidelines
Q37812344Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes
Q37496212Risks from Catheter Ablation of Atrial Fibrillation: A Review of Methods, Efficacy, and Safety
Q64072391Rivaroxaban in atrial fibrillation cardioversion: an update
Q37013005Robotic and magnetic navigation for atrial fibrillation ablation. How and why?
Q28075507Robotic magnetic navigation for ablation of human arrhythmias
Q38528051Robotic navigation for catheter ablation: benefits and challenges.
Q42925101Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers
Q33809189Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion
Q38011970Should rhythm control be preferred in younger atrial fibrillation patients?
Q37831854Sinus rhythm restoration and treatment success: insight from recent clinical trials.
Q35989632Stroke prevention in atrial fibrillation: warfarin faces its challengers
Q37293140Structural remodeling in atrial fibrillation.
Q92703557Subclinical and Asymptomatic Atrial Fibrillation: Current Evidence and Unsolved Questions in Clinical Practice
Q38685823Successful recovery of tachycardia-induced cardiomyopathy with severely depressed left ventricular systolic function by catheter ablation with mechanical hemodynamic support: a case report
Q30479334Surgery for Lone Atrial Fibrillation: Present State-of-the-Art
Q27022070Surgery for atrial fibrillation
Q35062034Surgical options in atrial fibrillation
Q38119110Surgical techniques used for the treatment of atrial fibrillation
Q89284209Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure
Q37523118Systematic review and meta-analysis of surgical ablation for atrial fibrillation during mitral valve surgery
Q64074292The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF
Q92434811The Impact of Repeated Cardioversions for Atrial Fibrillation on Stroke, Hospitalizations, and Catheter Ablation Outcomes
Q26747263The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation
Q36264955The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?
Q35197116The burden of atrial fibrillation in the Netherlands
Q39119910The burden of proof: The current state of atrial fibrillation prevention and treatment trials
Q38194112The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion
Q37402218The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation
Q35205261The impact of CHADS2 score on late stroke after the Cox maze procedure
Q90422408The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study
Q37968514The management of patients with atrial fibrillation and dronedarone's place in therapy
Q46184672The prevalence of sinus rhythm in patients with "permanent" atrial fibrillation
Q79370892The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease
Q57449367The role of the gap junction perinexus in cardiac conduction: Potential as a novel anti-arrhythmic drug target
Q36446911The safety of digoxin as a pharmacological treatment of atrial fibrillation.
Q84588920The surgical treatment of atrial fibrillation
Q36764580The worldwide social burden of atrial fibrillation: what should be done and where do we go?
Q26828753The year in review of clinical cardiac electrophysiology
Q57627876Therapie von Vorhofflimmern
Q37847185Treating arrhythmias: an expert opinion
Q37496298Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure
Q39195789Treatment Failure With Rhythm and Rate Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure: An AF-CHF Substudy
Q34884620Treatment of atrial fibrillation in every days practice
Q34307919Trends in the use of electrical cardioversion for atrial fibrillation: influence of major trials and guidelines on clinical practice
Q34505579Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
Q37126166Update on atrial fibrillation: part II.
Q35926637Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial
Q36437128Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis
Q37278794Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation
Q36764028Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent
Q47593262WITHDRAWN: Electrical cardioversion for atrial fibrillation and flutter.
Q38384893What can rhythm control therapy contribute to prognosis in atrial fibrillation?
Q81356754When, how, and why should sinus rhythm be restored in patients with persistent atrial fibrillation?
Q87301012[Medicinal rate control in atrial fibrillation]
Q82654632[Rhythm control - cardioversion]
Q82654665[Which therapy for which patient? In daily practice]

Search more.